Rituximab and statins

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages

  Carver, Joseph R ^a   Johnson, Tyler ^a   Schuster, Stephen J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

HUMAN; LETTER; LYMPHOMA; MEDICAL RECORD REVIEW; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; FOLLICULAR LYMPHOMA; LARGE CELL LYMPHOMA; NOTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; TREATMENT OUTCOME;

EID: 78049525128     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.0418     Document Type: Letter

References (5)

1. Nowakowski GS, Maurer MJ, Haberman TM, et al: Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 28:412-417, 2009
2. Winiarska M, Bil J, Wilczek E, et al: Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5:e64, 2008
3. Rabinowitz I: Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 26:5486, 2008
4. Carver JR, Schuster SJ, Glick JH: In reply. J Clin Oncol 26:5486, 2008
5. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)